| ORIGINAL ARTICLE |
|
| Year : 2011 | Volume
: 2
| Issue : 2 | Page : 3 |
|
|
Statins; a double weapon in treating dyslipidemic osteoporotic menopausal type 2 diabetic women
FE Amara1, NA Lachine1, A Hassab2, ME Meleis3, EY Moursy1, SA El-Sheikh1, MH Megallaa1, H Hassan1
1 Department of Internal Medicine. Alexandria University, Alexandria, Egypt
2 Department of Clinical Pathology Alexandria University, Alexandria, Egypt
3 Department of Gynecology & Obstetrics, Alexandria University, Alexandria, Egypt
Correspondence Address:
F E Amara
Emeritus Professor of Internal Medicine, Unit of Diabetes & Metabolism, Department of Internal Medicine, Alexandria University, Alexandria, Egypt
 Source of Support: None, Conflict of Interest: None
|
|
|
Recent reports have suggested the possible beneficial role of 3-hydroxy-3 methyl glutaryl Coenzyme-A (HMGCo-A) reductase inhibitors (Statins) in the management of osteoporosis. The aim of this work was to study the effect of statins; simvastatin and pravastatin, on bone mineral density (BMD) of dyslipidemic postmenopausal females with type 2 diabetes mellitus (T2DM) having osteoporosis. Thirty postmenopausal dyslipidemic type 2 diabetes females with no history of any disease or drug that can affect bone metabolism, were included in this study and classified into 2 groups. Group I received simvastatin 40 mg daily and group II received pravastatin 40mg daily, both for 6 months. Both, serum osteocalcin (a marker of bone formation) and urinary deoxypyridinoline (DPD) (a marker of bone resorption) were measured. Dual Energy X-ray Absorptiometry (DEXA) was used to assess BMD at 2 sites; the forearm (peripheral site) and the second & third lumbar vertebrae (axial site). Serum levels of osteocalcin and the BMD revealed significant increase and the urinary levels of DPD revealed significant decrease after 6 months of simvastatin therapy in group I, with mild change in the same parameters in group II, after 6 months of pravastatin administration. Yet these differences did not reach statistical significance. Our results confirmed the beneficial role of simvastatin in type 2 diabetes women with osteoporosis. However, further studies are needed to recognize the best effective dose as well as the possibility of using statins in combination with other currently used drugs in the treatment of osteoporosis.
|
|
|
|
| [PDF]* |
|
 |
|
